‘Research autopsy’ helps scientists study why some cancer therapies stop working

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Scientists at the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute of The Ohio State University Comprehensive Cancer Center are studying tissues collected within hours of death to gather clues as to why certain cancers are able to spread and evolve. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

With the recent FDA approval of daratumumab for high-risk smoldering multiple myeloma, the moment is ripe to revisit the evolution of our understanding of smoldering multiple myeloma. This development not only underscores the growing recognition of early intervention but also invites a broader reflection on the biological insights and therapeutic strategies that have shaped—and continue to shape—this transitional disease state.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login